Incretin Hormones and Obesity

Overview

Journal J Physiol

Specialty Physiology

Date 2024 Nov 22

PMID 39576749

Authors

Constanza Alcaino

Frank Reimann

Fiona M Gribble

Affiliations

Soon will be listed here.

Abstract

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) play critical roles in co-ordinating postprandial metabolism, including modulation of insulin secretion and food intake. They are secreted from enteroendocrine cells in the intestinal epithelium following food ingestion, and act at multiple target sites including pancreatic islets and the brain. With the recent development of agonists targeting GLP-1 and GIP receptors for the treatment of type 2 diabetes and obesity, and the ongoing development of new incretin-based drugs with improved efficacy, there is great interest in understanding the physiology and pharmacology of these hormones.

References

Egerod K, Engelstoft M, Grunddal K, Nohr M, Secher A, Sakata I . A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology. 2012; 153(12):5782-95. PMC: 7958714. DOI: 10.1210/en.2012-1595. View

Treichel A, Finholm I, Knutson K, Alcaino C, Whiteman S, Brown M . Specialized Mechanosensory Epithelial Cells in Mouse Gut Intrinsic Tactile Sensitivity. Gastroenterology. 2021; 162(2):535-547.e13. PMC: 8792331. DOI: 10.1053/j.gastro.2021.10.026. View

Santos-Hernandez M, Reimann F, Gribble F . Cellular mechanisms of incretin hormone secretion. J Mol Endocrinol. 2024; 72(4). PMC: 10959011. DOI: 10.1530/JME-23-0112. View

Lebrun L, Lenaerts K, Kiers D, Pais de Barros J, Le Guern N, Plesnik J . Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion. Cell Rep. 2017; 21(5):1160-1168. DOI: 10.1016/j.celrep.2017.10.008. View

Ogawa E, Hosokawa M, Harada N, Yamane S, Hamasaki A, Toyoda K . The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice. Biochem Biophys Res Commun. 2010; 404(1):115-20. DOI: 10.1016/j.bbrc.2010.11.077. View

Zhou J, Livak M, Bernier M, Muller D, Carlson O, Elahi D . Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab. 2007; 293(2):E538-47. PMC: 2640485. DOI: 10.1152/ajpendo.00070.2007. View

Benjamin M, McKay D, Yang P, Cameron H, Perdue M . Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000; 47(1):112-9. PMC: 1727982. DOI: 10.1136/gut.47.1.112. View

Huang K, Acosta A, Ghidewon M, McKnight A, Almeida M, Nyema N . Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024; 632(8025):585-593. DOI: 10.1038/s41586-024-07685-6. View

Williams E, Chang R, Strochlic D, Umans B, Lowell B, Liberles S . Sensory Neurons that Detect Stretch and Nutrients in the Digestive System. Cell. 2016; 166(1):209-21. PMC: 4930427. DOI: 10.1016/j.cell.2016.05.011. View

10.

Beumer J, Puschhof J, Bauza-Martinez J, Martinez-Silgado A, Elmentaite R, James K . High-Resolution mRNA and Secretome Atlas of Human Enteroendocrine Cells. Cell. 2020; 182(4):1062-1064. DOI: 10.1016/j.cell.2020.08.005. View

11.

Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D . Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2011; 61(1):187-96. PMC: 3237647. DOI: 10.2337/db11-1029. View

12.

Bluher M, Rosenstock J, Hoefler J, Manuel R, Hennige A . Dose-response effects on HbA and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2023; 67(3):470-482. PMC: 10844353. DOI: 10.1007/s00125-023-06053-9. View

13.

McLean B, Wong C, Campbell J, Hodson D, Trapp S, Drucker D . Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocr Rev. 2020; 42(2):101-132. PMC: 7958144. DOI: 10.1210/endrev/bnaa032. View

14.

Pocai A . Action and therapeutic potential of oxyntomodulin. Mol Metab. 2014; 3(3):241-51. PMC: 3986661. DOI: 10.1016/j.molmet.2013.12.001. View

15.

Zhang C, Vincelette L, Reimann F, Liberles S . A brainstem circuit for nausea suppression. Cell Rep. 2022; 39(11):110953. PMC: 9260880. DOI: 10.1016/j.celrep.2022.110953. View

16.

Adriaenssens A, Biggs E, Darwish T, Tadross J, Sukthankar T, Girish M . Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake. Cell Metab. 2019; 30(5):987-996.e6. PMC: 6838660. DOI: 10.1016/j.cmet.2019.07.013. View

17.

Mawe G, Hoffman J . Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013; 10(8):473-86. PMC: 4048923. DOI: 10.1038/nrgastro.2013.105. View

18.

Lu V, Gribble F, Reimann F . Free Fatty Acid Receptors in Enteroendocrine Cells. Endocrinology. 2018; 159(7):2826-2835. DOI: 10.1210/en.2018-00261. View

19.

Manchanda Y, Tomas A . New insights into the regulation of GIPR signalling. Nat Rev Endocrinol. 2024; 20(10):571-572. DOI: 10.1038/s41574-024-01027-2. View

20.

Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C . Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology. 1991; 101(2):503-11. DOI: 10.1016/0016-5085(91)90031-f. View